Skip to main content

PROCEPT BioRobotics Appoints Mary Garrett to Board of Directors

Written by Customer Service on . Posted in Public Companies.

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board of Directors.

Ms. Garrett most recently served on the board of Hillrom Corporation which was acquired by Baxter International Inc. in December 2021. Ms. Garrett was the governance committee chair and served on the audit committee of Hill-Rom. She also previously served as a board member and was on the audit committee of Ethan Allen Interiors, Inc. Prior to these roles and her retirement in 2015, Ms. Garrett was the Chief Marketing Officer, Global Markets for IBM Corporation.

“Ms. Garrett’s impressive understanding of the technology industry and expertise in organizational development make her ideally suited to join PROCEPT’s board,” said Reza Zadno, PROCEPT CEO. “Her prior experience serving in multiple roles on public company boards and as a global marketing leader in large and developing markets will be very beneficial to our growing company.”

“I am pleased to join PROCEPT’s Board of Directors and be a part of a company that is using technology to advance patient care. The company’s rapid growth and ability to capture a large and expanding market are exciting, and I am looking forward to helping PROCEPT achieve these goals,” said Ms. Garrett.

With the appointment of Ms. Garrett, the Board of Directors of PROCEPT BioRobotics Corporation increased the number of directors on the Board to nine members.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.